Sarvari Venkata Yellapragada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sarvari Venkata Yellapragada has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- André Catic
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
20 shared publications - Ergun Sahin
Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA
20 shared publications - Laure Maneix
Baylor College of Medicine
20 shared publications - Premal Lulla
Baylor College of Medicine
20 shared publications - Shannon E. Moree
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
20 shared publications - Fabio Stossi
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
19 shared publications
Latest Publications
- Open Access
- 7 October 2024
- Published by SAABRON PRESS in Clinical Hematology International
- Vol. 6 (4) , 11-18
Pathophysiology and Treatments of Complications of Waldenström’s Macroglobulinemia
Waldenstrom’s macroglobulinemia (WM) or lymphoplasmacytic lymphoma is a B-cell malignancy characterized by lymphoplasmacytic cells in the bone marrow that secrete high amounts of immunoglobulin (Ig) M. The large pentameric structure of IgM leads to a variety of unique complications in WM, such as hyperviscosity syndrome, cryoglobulinemia and sensory neuropathy. Furthermore, malignant cells can infiltrate the central nervous system and lead to a variety of neurological complications, also known as Bing Neel Syndrome. Because of the unique pathophysiology of WM and these complications, their diagnostic work up and treatment regimens vary greatly. Given the rarity of the disease and their complications, there are little to no randomized controlled trials regarding treatments of these complications and, therefore, suggested treatment regimens are usually based on observational studies. In this case series, we will present three cases of WM, each with their own unique complication, and discuss the pathophysiology along with current and future treatment options for each of the complications presented.
- 7 October 2024
- Published by SAABRON PRESS in Clinical Hematology International
- Vol. 6 (4) , 11-18
Open AccessPathophysiology and Treatments of Complications of Waldenström’s Macroglobulinemia
Waldenstrom’s macroglobulinemia (WM) or lymphoplasmacytic lymphoma is a B-cell malignancy characterized by lymphoplasmacytic cells in the bone marrow that secrete high amounts of immunoglobulin (Ig) M. The large pentameric structure of IgM leads to a variety of unique complications in WM, such as hyperviscosity syndrome, cryoglobulinemia and sensory neuropathy. Furthermore, malignant cells can infiltrate the central nervous system and lead to a variety of neurological complications, also known as Bing Neel Syndrome. Because of the unique pathophysiology of WM and these complications, their diagnostic work up and treatment regimens vary greatly. Given the rarity of the disease and their complications, there are little to no randomized controlled trials regarding treatments of these complications and, therefore, suggested treatment regimens are usually based on observational studies. In this case series, we will present three cases of WM, each with their own unique complication, and discuss the pathophysiology along with current and future treatment options for each of the complications presented.
- 5 April 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (8) , 523-530
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States
- 5 April 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (8) , 523-530
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibitors have become the standard of care for multiple myeloma. Blocking protein degradation particularly perturbs the homeostasis of short-lived polypeptides such as transcription factors and epigenetic regulators. To determine how proteasome inhibitors directly impact gene regulation, we performed an integrative genomics study in multiple myeloma cells. We discovered that proteasome inhibitors reduce the turnover of DNA-associated proteins and repress genes necessary for proliferation through epigenetic silencing. Specifically, proteasome inhibition results in the localized accumulation of histone deacetylase 3 (HDAC3) at defined genomic sites, which reduces H3K27 acetylation and increases chromatin condensation. The loss of active chromatin at super-enhancers critical for multiple myeloma, including the super-enhancer controlling the proto-oncogene c-MYC, reduces metabolic activity and cancer cell growth. Epigenetic silencing is attenuated by HDAC3 depletion, suggesting a tumor-suppressive element of this deacetylase in the context of proteasome inhibition. In the absence of treatment, HDAC3 is continuously removed from DNA by the ubiquitin ligase Seven in Absentia Homolog 2 (SIAH2). Overexpression of SIAH2 increases H3K27 acetylation at c-MYC–controlled genes, increases metabolic output, and accelerates cancer cell proliferation. Our studies indicate a novel therapeutic function of proteasome inhibitors in multiple myeloma by reshaping the epigenetic landscape in an HDAC3-dependent manner. As a result, blocking the proteasome effectively antagonizes c-MYC and the genes controlled by this proto-oncogene.Significance:Integrative genomics reveals that a key function of proteasome inhibitors involves limiting the activity of MYC and MYC-dependent genes through epigenetic repression.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibitors have become the standard of care for multiple myeloma. Blocking protein degradation particularly perturbs the homeostasis of short-lived polypeptides such as transcription factors and epigenetic regulators. To determine how proteasome inhibitors directly impact gene regulation, we performed an integrative genomics study in multiple myeloma cells. We discovered that proteasome inhibitors reduce the turnover of DNA-associated proteins and repress genes necessary for proliferation through epigenetic silencing. Specifically, proteasome inhibition results in the localized accumulation of histone deacetylase 3 (HDAC3) at defined genomic sites, which reduces H3K27 acetylation and increases chromatin condensation. The loss of active chromatin at super-enhancers critical for multiple myeloma, including the super-enhancer controlling the proto-oncogene c-MYC, reduces metabolic activity and cancer cell growth. Epigenetic silencing is attenuated by HDAC3 depletion, suggesting a tumor-suppressive element of this deacetylase in the context of proteasome inhibition. In the absence of treatment, HDAC3 is continuously removed from DNA by the ubiquitin ligase Seven in Absentia Homolog 2 (SIAH2). Overexpression of SIAH2 increases H3K27 acetylation at c-MYC–controlled genes, increases metabolic output, and accelerates cancer cell proliferation. Our studies indicate a novel therapeutic function of proteasome inhibitors in multiple myeloma by reshaping the epigenetic landscape in an HDAC3-dependent manner. As a result, blocking the proteasome effectively antagonizes c-MYC and the genes controlled by this proto-oncogene.Significance:Integrative genomics reveals that a key function of proteasome inhibitors involves limiting the activity of MYC and MYC-dependent genes through epigenetic repression.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Genome-wide analysis of acute effects of proteasome inhibition on transcription and chromatin in MM cells.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Genome-wide analysis of acute effects of proteasome inhibition on transcription and chromatin in MM cells.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
The SIAH2 ubiquitin ligase antagonizes HDAC3-mediated repression in MM cells.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
The SIAH2 ubiquitin ligase antagonizes HDAC3-mediated repression in MM cells.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
DNA site-specific stabilization of HDAC3 by proteasome inhibition in MM cells.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
DNA site-specific stabilization of HDAC3 by proteasome inhibition in MM cells.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibition represses cell proliferation and mitochondrial activity in MM.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibition represses cell proliferation and mitochondrial activity in MM.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibition down-regulates cell cycle and mitochondrial gene expression in three different MM cell lines.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Proteasome inhibition down-regulates cell cycle and mitochondrial gene expression in three different MM cell lines.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
HDAC3 mediates repression of the H3K27ac mark at super-enhancers of genes relevant for MM biology following proteasome inhibition.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
HDAC3 mediates repression of the H3K27ac mark at super-enhancers of genes relevant for MM biology following proteasome inhibition.